+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bovine Mastitis Market by Product Type, Application, Distribution Channel, End User, Route Of Administration, Dosage Form - Global Forecast to 2030- Product Image
Bovine Mastitis Market by Product Type, Application, Distribution Channel, End User, Route Of Administration, Dosage Form - Global Forecast to 2030- Product Image
Sale

Bovine Mastitis Market by Product Type, Application, Distribution Channel, End User, Route Of Administration, Dosage Form - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6084136
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bovine Mastitis Market grew from USD 1.48 billion in 2024 to USD 1.57 billion in 2025. It is expected to continue growing at a CAGR of 5.90%, reaching USD 2.08 billion by 2030.

Unlocking the Complexities of Bovine Mastitis Management

The dairy industry stands at a crucial juncture where animal health directly influences production efficiency, consumer confidence, and regulatory compliance. Among the most pervasive challenges facing dairy farmers is bovine mastitis, an inflammation of the mammary gland that compromises milk yield, quality, and animal welfare. As pathogenic strains evolve and consumer pressure on antibiotic stewardship intensifies, stakeholders are forced to recalibrate their strategies for prevention, diagnosis, and treatment.

This executive summary distills the latest developments in pathogen management, compliance dynamics, and competitive forces shaping the mastitis therapeutics landscape. It offers an integrative overview of emerging treatment modalities-from advanced antibiotics and teat sealants to next-generation vaccines-and tracks shifts in channel strategies, tariff impacts, and regional priorities. By presenting nuanced segmentation and profiling leading players, the report equips decision-makers with actionable intelligence to navigate uncertainty and drive strategic investments.

Evolving Dynamics Reshaping Mastitis Treatment Protocols

The mastitis treatment landscape is undergoing a profound transformation driven by technological innovation, regulatory realignment, and shifting farmer expectations. Precision monitoring platforms are now providing real-time data on udder health, enabling early intervention and minimizing blanket antibiotic usage. These digital tools dovetail with herd management software to deliver predictive analytics, empowering veterinarians and farmers to tailor treatments to individual animals rather than entire herds.

Concurrently, regulatory agencies across major markets are tightening restrictions on antibiotic residues, prompting a surge in demand for non-antibiotic solutions. Teat sealants are gaining traction as a preventive barrier during the dry period, while vaccine pipelines are accelerating toward commercialization. This shift not only supports antimicrobial stewardship goals but also encourages partnerships between pharmaceutical companies and biotech firms to co-develop novel immunotherapies. Collectively, these shifts are redefining treatment protocols and setting new benchmarks for efficacy and safety.

Assessing the 2025 Trade Tariffs Impact on Treatment Supply Chains

The introduction of new trade tariffs in 2025 has added complexity to the procurement and distribution of mastitis treatments. Antibiotics, many of which rely on specialized raw materials sourced internationally, have experienced cost pressures as import duties climb. These higher price points have rippled through to veterinary practices and farm budgets, prompting end users to explore domestic alternatives and bulk procurement strategies to mitigate expense volatility.

Vaccines and teat sealants have likewise been affected, as producers adjust their supply chains to accommodate rising duties and logistical bottlenecks. In response, leading suppliers have diversified manufacturing footprints and established regional distribution centers to maintain consistent access. Despite these efforts, smaller veterinary distributors continue to face margin squeezes, encouraging consolidation and strategic alliances to spread tariff risks. Looking ahead, the ability to offset tariff impacts through localized production and integrated supply networks will be a key differentiator for resilient market participants.

Deep Dive into Product Application and End User Segmentation

Insight into product segmentation reveals distinct performance drivers across antibiotics, teat sealants, and vaccines. Within the antibiotics segment, demand for beta lactams remains dominant, led by cephalosporins and penicillins due to their broad-spectrum activity. Tetracyclines and aminoglycosides continue to serve critical niches, particularly in herds challenged by resistant strains. Teat sealants are increasingly recognized for their preventive value during the dry cow period, forming an essential component of integrated mastitis control plans.

Application-based trends underscore the divergent needs of dry cow therapy versus lactation therapy. During the dry period, longer-acting formulations such as ointments and powders offer sustained protection, while lactation treatments favor fast-acting solutions administered intramammary. Distribution patterns further reflect this dichotomy: direct sales channels facilitate large-scale farm adoption of preventative treatments, whereas distributors and online channels cater to on-demand lactation interventions. End users span dairy farms that prioritize cost-efficiency and volume needs alongside veterinary clinics that emphasize clinical support and customized regimens.

Route of administration remains a key strategic lever. Intramammary approaches dominate owing to targeted delivery and reduced systemic exposure, but parenteral administration is gaining ground for its rapid systemic effect and ease of use in remote or extensive farming systems. The dosage form landscape features solutions as the primary choice for immediate relief, while powders and ointments fulfill the need for prolonged prophylaxis. By aligning product design with specific use cases across segments, companies can optimize their portfolios for maximum impact.

Regional Variations Shaping Market Priorities Globally

Regional analysis highlights the Americas as a mature and innovation-driven market, where advanced veterinary infrastructure and high herd health standards support rapid adoption of precision monitoring and premium treatments. Producers here are at the forefront of integrating digital herd management with targeted therapy protocols, driving premiumization of vaccine and sealant portfolios.

In Europe, the Middle East, and Africa, stringent regulatory frameworks are reshaping antibiotic usage, fueling investment in alternative therapies and driving collaborations between biotech innovators and established pharmaceutical players. Farmers in this region are increasingly embracing teat sealants and emerging vaccine platforms to comply with antimicrobial reduction mandates while safeguarding milk quality.

The Asia-Pacific region presents a dynamic blend of large industrial dairy operations and smallholder farms. Rapid growth in milk consumption has spurred demand for cost-effective lactation therapies, with online distribution channels emerging as a vital conduit for rapid restocking. Parenteral formulations are particularly favored in areas with limited access to specialized dairy equipment, reflecting the diverse needs of a populous and evolving market.

Competitive Landscape and Strategic Positioning of Key Players

The competitive landscape is anchored by multinational leaders investing heavily in R&D and global distribution networks. One top-tier player has expanded its portfolio to include advanced intramammary teat sealants that leverage novel formulation technologies for extended efficacy. Another key company is forging partnerships with biotech firms to accelerate vaccine development targeting Staphylococcus aureus and Escherichia coli, two of the most prevalent mastitis pathogens.

Mid-sized innovators are carving out niches by focusing on specialty antibiotics and digital support services, offering cloud-based herd health dashboards and diagnostic tools. These offerings complement traditional product lines and strengthen customer relationships through value-added service bundles. Meanwhile, regional distributors are deepening their local expertise, co-creating training programs with veterinary schools and dairy cooperatives to reinforce best practices and drive brand loyalty.

Across the board, mergers and acquisitions remain a strategic lever, as companies seek to broaden their geographic footprint and diversify their treatment portfolios. Strategic equity investments in early-stage biotech ventures signal a longer-term commitment to immunotherapeutic solutions that promise to redefine mastitis control paradigms.

Strategic Imperatives for Industry Leaders to Drive Growth

Industry leaders should prioritize the development of integrated treatment suites that combine precision diagnostics, targeted therapeutics, and herd management services. By aligning product portfolios across antibiotics, teat sealants, and vaccines, companies can offer comprehensive mastitis control programs that reduce reliance on any single modality. Strengthening partnerships with veterinary practitioners and dairy cooperatives will further embed these programs into routine farm operations.

To counter tariff pressures, businesses must diversify manufacturing locations and invest in regional production facilities. Localized supply chains not only shield against import duties but also foster closer engagement with end users to tailor formulations for regional disease profiles and husbandry practices. Concurrently, expanding online channels and direct sales teams can expedite product delivery and enhance customer responsiveness.

R&D investments should be channeled toward next-generation immunotherapies and non-antibiotic alternatives, particularly in regions facing the strictest antimicrobial regulations. Collaborative research with academic institutions and biotech firms can accelerate time to market, while co-development agreements reduce the burden of upfront investment. Finally, companies should refine pricing strategies to balance affordability in cost-sensitive markets with premiumization in advanced economies, ensuring sustainable growth across diverse geographies.

Rigorous Research Framework Underpinning Our Market Analysis

The foundation of this analysis rests on a hybrid research approach that integrates primary and secondary data sources. Primary insights were gleaned from in-depth interviews with practicing veterinarians, dairy farm managers, and distribution executives across key regions. These conversations provided real-world perspectives on treatment efficacy, channel performance, and emerging challenges.

Secondary research drew upon regulatory filings, industry publications, peer-reviewed journals, and corporate disclosures to map technological advancements, market regulations, and competitor strategies. Data points were cross-validated through triangulation techniques to ensure accuracy and relevance. Segmentation frameworks were constructed around product type, application, distribution channel, end user, route of administration, and dosage form to deliver a granular understanding of market dynamics.

Qualitative findings were supplemented by trend analysis, scenario planning, and expert panels to validate assumptions and interpret complex interactions. The research process adhered to stringent quality controls, including peer review and methodological audits, to maintain objectivity and credibility.

Bringing Insights Together to Navigate Mastitis Market Challenges

Bovine mastitis will remain a focal point for dairy industry stakeholders as antimicrobial stewardship, animal welfare, and production efficiency converge. The interplay of technological innovation, shifting regulatory mandates, and evolving farmer preferences demands a proactive stance. Companies that successfully integrate digital diagnostics, diversified therapeutic portfolios, and resilient supply chains will be best positioned to capture emerging opportunities.

Regional distinctions underscore the necessity of tailored strategies: while the Americas lead in premium solutions, EMEA’s regulatory push favors non-antibiotic modalities, and Asia-Pacific’s scale and cost sensitivities drive demand for accessible lactation therapies. At the same time, the competitive arena is intensifying as established players expand their immunotherapy pipelines and nimble entrants leverage digital platforms to differentiate offerings.

In this dynamic context, actionable insights and a flexible roadmap are indispensable. Organizations that embrace collaboration, prioritize next-generation treatments, and commit to continuous innovation will shape the future of mastitis management and secure sustainable growth in an increasingly complex marketplace.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Antibiotics
      • Aminoglycosides
      • Beta Lactams
        • Cephalosporins
        • Penicillins
      • Tetracyclines
    • Teat Sealants
    • Vaccines
  • Application
    • Dry Cow Therapy
    • Lactation Therapy
  • Distribution Channel
    • Direct Sales
    • Distributors
    • Online Channels
  • End User
    • Dairy Farms
    • Veterinary Clinics
  • Route Of Administration
    • Intramammary
    • Parenteral
  • Dosage Form
    • Ointment
    • Powder
    • Solution
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Zoetis Inc.
  • Merck & Co., Inc.
  • Elanco Animal Health Incorporated
  • Boehringer Ingelheim International GmbH
  • Ceva Santé Animale S.A.
  • Phibro Animal Health Corporation
  • Vetoquinol S.A.
  • Huvepharma NV
  • HIPRA, S.A.
  • IDEXX Laboratories, Inc.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bovine Mastitis Market, by Product Type
8.1. Introduction
8.2. Antibiotics
8.2.1. Aminoglycosides
8.2.2. Beta Lactams
8.2.2.1. Cephalosporins
8.2.2.2. Penicillins
8.2.3. Tetracyclines
8.3. Teat Sealants
8.4. Vaccines
9. Bovine Mastitis Market, by Application
9.1. Introduction
9.2. Dry Cow Therapy
9.3. Lactation Therapy
10. Bovine Mastitis Market, by Distribution Channel
10.1. Introduction
10.2. Direct Sales
10.3. Distributors
10.4. Online Channels
11. Bovine Mastitis Market, by End User
11.1. Introduction
11.2. Dairy Farms
11.3. Veterinary Clinics
12. Bovine Mastitis Market, by Route Of Administration
12.1. Introduction
12.2. Intramammary
12.3. Parenteral
13. Bovine Mastitis Market, by Dosage Form
13.1. Introduction
13.2. Ointment
13.3. Powder
13.4. Solution
14. Americas Bovine Mastitis Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Bovine Mastitis Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Bovine Mastitis Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Zoetis Inc.
17.3.2. Merck & Co., Inc.
17.3.3. Elanco Animal Health Incorporated
17.3.4. Boehringer Ingelheim International GmbH
17.3.5. Ceva Santé Animale S.A.
17.3.6. Phibro Animal Health Corporation
17.3.7. Vetoquinol S.A.
17.3.8. Huvepharma NV
17.3.9. HIPRA, S.A.
17.3.10. IDEXX Laboratories, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. BOVINE MASTITIS MARKET MULTI-CURRENCY
FIGURE 2. BOVINE MASTITIS MARKET MULTI-LANGUAGE
FIGURE 3. BOVINE MASTITIS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BOVINE MASTITIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BOVINE MASTITIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BOVINE MASTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BOVINE MASTITIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BOVINE MASTITIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS BOVINE MASTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS BOVINE MASTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES BOVINE MASTITIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES BOVINE MASTITIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BOVINE MASTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BOVINE MASTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC BOVINE MASTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC BOVINE MASTITIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. BOVINE MASTITIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. BOVINE MASTITIS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BOVINE MASTITIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BOVINE MASTITIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BOVINE MASTITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BOVINE MASTITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BOVINE MASTITIS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BOVINE MASTITIS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BOVINE MASTITIS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BOVINE MASTITIS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BOVINE MASTITIS MARKET SIZE, BY TEAT SEALANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BOVINE MASTITIS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BOVINE MASTITIS MARKET SIZE, BY DRY COW THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BOVINE MASTITIS MARKET SIZE, BY LACTATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BOVINE MASTITIS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BOVINE MASTITIS MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BOVINE MASTITIS MARKET SIZE, BY DAIRY FARMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BOVINE MASTITIS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BOVINE MASTITIS MARKET SIZE, BY INTRAMAMMARY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BOVINE MASTITIS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BOVINE MASTITIS MARKET SIZE, BY OINTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BOVINE MASTITIS MARKET SIZE, BY POWDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BOVINE MASTITIS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS BOVINE MASTITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES BOVINE MASTITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 52. CANADA BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 53. CANADA BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 54. CANADA BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 55. CANADA BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. CANADA BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. CANADA BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. CANADA BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 60. MEXICO BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 61. MEXICO BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 62. MEXICO BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 63. MEXICO BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. MEXICO BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. MEXICO BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. MEXICO BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. MEXICO BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA BOVINE MASTITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 101. GERMANY BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 102. GERMANY BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 103. GERMANY BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 104. GERMANY BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. GERMANY BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. GERMANY BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. GERMANY BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. GERMANY BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 109. FRANCE BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 110. FRANCE BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 111. FRANCE BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 112. FRANCE BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. FRANCE BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. FRANCE BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. FRANCE BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. FRANCE BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 125. ITALY BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 126. ITALY BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 127. ITALY BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 128. ITALY BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. ITALY BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. ITALY BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. ITALY BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. ITALY BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 133. SPAIN BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 134. SPAIN BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 135. SPAIN BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 136. SPAIN BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. SPAIN BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. SPAIN BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. SPAIN BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. SPAIN BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 149. SAUDI ARABIA BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 157. SOUTH AFRICA BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 165. DENMARK BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 166. DENMARK BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 167. DENMARK BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 168. DENMARK BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. DENMARK BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. DENMARK BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. DENMARK BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. DENMARK BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 181. QATAR BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 182. QATAR BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 183. QATAR BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 184. QATAR BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. QATAR BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. QATAR BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. QATAR BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. QATAR BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 189. FINLAND BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 190. FINLAND BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 191. FINLAND BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 192. FINLAND BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. FINLAND BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. FINLAND BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. FINLAND BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. FINLAND BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 197. SWEDEN BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 213. EGYPT BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 214. EGYPT BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 215. EGYPT BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 216. EGYPT BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. EGYPT BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. EGYPT BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. EGYPT BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. EGYPT BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 221. TURKEY BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 222. TURKEY BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 223. TURKEY BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 224. TURKEY BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. TURKEY BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. TURKEY BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. TURKEY BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. TURKEY BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 229. ISRAEL BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 237. NORWAY BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 238. NORWAY BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 239. NORWAY BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 240. NORWAY BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 241. NORWAY BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. NORWAY BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. NORWAY BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. NORWAY BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 245. POLAND BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 246. POLAND BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 247. POLAND BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 248. POLAND BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 249. POLAND BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 250. POLAND BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. POLAND BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. POLAND BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC BOVINE MASTITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 270. CHINA BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 271. CHINA BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 272. CHINA BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 273. CHINA BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 274. CHINA BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. CHINA BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. CHINA BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. CHINA BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 278. INDIA BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 279. INDIA BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 280. INDIA BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 281. INDIA BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 282. INDIA BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. INDIA BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. INDIA BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. INDIA BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 286. JAPAN BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 287. JAPAN BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 288. JAPAN BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 289. JAPAN BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 290. JAPAN BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. JAPAN BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. JAPAN BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. JAPAN BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 294. AUSTRALIA BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 295. AUSTRALIA BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 296. AUSTRALIA BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 302. SOUTH KOREA BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 303. SOUTH KOREA BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 310. INDONESIA BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 311. INDONESIA BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 312. INDONESIA BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 313. INDONESIA BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 318. THAILAND BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 319. THAILAND BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 320. THAILAND BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 321. THAILAND BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 322. THAILAND BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 323. THAILAND BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 324. THAILAND BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 325. THAILAND BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 326. PHILIPPINES BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 327. PHILIPPINES BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 328. PHILIPPINES BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 329. PHILIPPINES BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 330. PHILIPPINES BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 331. PHILIPPINES BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 332. PHILIPPINES BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 333. PHILIPPINES BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 334. MALAYSIA BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 335. MALAYSIA BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 336. MALAYSIA BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 337. MALAYSIA BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 338. MALAYSIA BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 339. MALAYSIA BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 341. MALAYSIA BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 342. SINGAPORE BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 343. SINGAPORE BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 344. SINGAPORE BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 345. SINGAPORE BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 346. SINGAPORE BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 347. SINGAPORE BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 348. SINGAPORE BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 349. SINGAPORE BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 350. VIETNAM BOVINE MASTITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 351. VIETNAM BOVINE MASTITIS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 352. VIETNAM BOVINE MASTITIS MARKET SIZE, BY BETA LACTAMS, 2018-2030 (USD MILLION)
TABLE 353. VIETNAM BOVINE MASTITIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 354. VIETNAM BOVINE MASTITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 355. VIETNAM BOVINE MASTITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 356. VIETNAM BOVINE MASTITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 357. VIETNAM BOVINE MASTITIS MARKET SIZE, BY DOSAGE FORM, 20

Companies Mentioned

The companies profiled in this Bovine Mastitis market report include:
  • Zoetis Inc.
  • Merck & Co., Inc.
  • Elanco Animal Health Incorporated
  • Boehringer Ingelheim International GmbH
  • Ceva Santé Animale S.A.
  • Phibro Animal Health Corporation
  • Vetoquinol S.A.
  • Huvepharma NV
  • HIPRA, S.A.
  • IDEXX Laboratories, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages183
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.57 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.08 Billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Bovine Mastitis Market Size, Share & Trends Analysis Report By Product (Pharmaceuticals, Diagnostics), By Route Of Administration (Intra-Mammary, Systemic), By Therapy, By Type, By End-use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Bovine Mastitis Market Size, Share & Trends Analysis Report By Product (Pharmaceuticals, Diagnostics), By Route Of Administration (Intra-Mammary, Systemic), By Therapy, By Type, By End-use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Bovine Mastitis Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Bovine Mastitis Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From
Bovine Mastitis Treatment System - Global Strategic Business Report - Product Image

Bovine Mastitis Treatment System - Global Strategic Business Report

  • Report
  • 366 Pages
  • Global
From
Elsevier's Review for the NAVLE, 1st Edition - Product Image

Elsevier's Review for the NAVLE, 1st Edition

  • Book

About the Bovine Mastitis Drug Market

Bovine Mastitis Drug is a type of animal pharmaceutical used to treat mastitis, an inflammation of the mammary glands in cows. It is a common and costly disease in dairy herds, and can lead to decreased milk production, increased culling, and increased veterinary costs. Bovine Mastitis Drugs are typically administered intramammary, and can be either systemic or topical. Systemic drugs are absorbed into the bloodstream and distributed throughout the body, while topical drugs are applied directly to the affected area. Common active ingredients in Bovine Mastitis Drugs include antibiotics, anti-inflammatory agents, and antifungals. Some companies in the Bovine Mastitis Drug market include Elanco, Merck Animal Health, Zoetis, Boehringer Ingelheim, and Bayer Animal Health. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.